Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Organoid Drug Sensitivity Testing to Guide Treatment in Unresectable Biliary Tract Cancers
NCT07351591Phase 2Not yet recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Jan 2026
- Primary completion
- Oct 2026
01
Overview
Phase 2, open-label trial in biliary tract cancer (BTC) (2 arms), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoints: Objective Response Rate up to 3 years and Progression-Free Survival up to 3 years. Planned start Jan 2026; status: not yet recruiting.
02
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07351591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07351591.